Evidence map›Paper›PMID 36601480›Full record

ArticleFrontiers in oncology2022

Spatial heterogeneity of cancer associated protein expression in immunohistochemically stained images as an improved prognostic biomarker.

Henrik Failmezger, Harald Hessel, Ansh Kapil, Günter Schmidt, Nathalie Harder

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Henrik FailmezgerResearch & Development Early Oncology Translational Medicine, Computational Pathology, AstraZeneca Computational Pathology GmbH, Munich, Germany.
Harald HesselResearch & Development Early Oncology Translational Medicine, Computational Pathology, AstraZeneca Computational Pathology GmbH, Munich, Germany.
Ansh KapilResearch & Development Early Oncology Translational Medicine, Computational Pathology, AstraZeneca Computational Pathology GmbH, Munich, Germany.
Günter SchmidtResearch & Development Early Oncology Translational Medicine, Computational Pathology, AstraZeneca Computational Pathology GmbH, Munich, Germany.
Nathalie HarderResearch & Development Early Oncology Translational Medicine, Computational Pathology, AstraZeneca Computational Pathology GmbH, Munich, Germany.
AstraZeneca (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of new tumor biomarkers for patient stratification before therapy, for monitoring of disease progression, and for characterization of tumor biology plays a crucial role in cancer research. The status of these biomarkers is mostly scored manually by a pathologist and such scores typically, do not consider the spatial heterogeneity of the protein's expression in the tissue. Using advanced image analysis methods, marker expression can be determined quantitatively with high accuracy and reproducibility on a per-cell level. To aggregate such per-cell marker expressions on a patient level, the expression values for single cells are usually averaged for the whole tissue. However, averaging neglects the spatial heterogeneity of the marker expression in the tissue. We present two novel approaches for quantitative scoring of spatial marker expression heterogeneity. The first approach is based on a co-occurrence analysis of the marker expression in neighboring cells. The second approach accounts for the local variability of the protein's expression by tiling the tissue with a regular grid and assigning local spatial heterogeneity phenotypes per tile. We apply our novel scores to quantify the spatial expression of four different membrane markers, i.e., HER2, CMET, CD44, and EGFR in immunohistochemically (IHC) stained tissue sections of colorectal cancer patients. We evaluate the prognostic relevance of our spatial scores in this cohort and show that the spatial heterogeneity scores clearly outperform the marker expression average as a prognostic factor (CMET: p-value=0.01 vs. p-value=0.3).

Indexed as

digital pathologyimmunohistochemistryprognostic biomarkerspatial heterogeneityspatial statistics

Identifiers

PMID36601480
PMCPMC9806230
OpenAlexW4313389551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.